NCT01511237 (PHPT-5) is a Phase 3 clinical trial of Nevirapine, zidovudine, lamivudine in HIV Infections, sponsored by Institut de Recherche pour le Developpement.

Who is sponsoring NCT01511237?

NCT01511237 is sponsored by Institut de Recherche pour le Developpement.

What drugs are being tested in NCT01511237?

Interventions in NCT01511237: Nevirapine, zidovudine, lamivudine.

What condition does NCT01511237 study?

NCT01511237 studies HIV Infections.

Is NCT01511237 still recruiting?

NCT01511237 is currently completed. Last updated 20 October 2021.

Last reviewed 2021-10-20 · How we verify

NCT01511237: PHPT-5

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PHPT-5 Second Phase: Perinatal Antiretroviral Intensification for the Prevention of Mother-to-child Transmission of HIV in Thai Women Having Received Less Than 8 Weeks of HAART During Pregnancy

Completed Phase 3 Last updated 20 October 2021

What this trial tests

Phase 3 trial testing Nevirapine, zidovudine, lamivudine in HIV Infections in 379 participants. Completed in 1 March 2017.

Timeline

1 December 2011

Primary endpoint
1 June 2015

1 March 2017

Quick facts

Lead sponsor	Institut de Recherche pour le Developpement
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	379
Start date	1 December 2011
Primary completion	1 June 2015
Estimated completion	1 March 2017
Sites	36 locations across Thailand

Drugs / interventions tested

Nevirapine, zidovudine, lamivudine — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Institut de Recherche pour le Developpement — full company profile →

Who can join

18 and older, female only, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Rate of perinatal HIV transmission
Time frame: 6 months
HIV DNA PCR analysis at birth, 2 weeks, 1, 2, 4 and 6 months of age

Sponsor's own description

The purpose is to evaluate the efficacy of maternal and infant perinatal antiretroviral prophylaxis intensification for the prevention of mother-to-child intrapartum transmission of HIV-1 in women receiving less than 8 weeks of antiretroviral prophylaxis during pregnancy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
Cressey TR, Punyawudho B, Le Coeur S, Jourdain G, et al · · 2017 · cited 14× · PMID 28489732 · DOI 10.1097/qai.0000000000001447
Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.
Lallemant M, Amzal B, Sripan P, Urien S, et al · · 2020 · cited 6× · PMID 32205720 · DOI 10.1097/qai.0000000000002350
Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
Sripan P, Le Coeur S, Ingsrisawang L, Cressey TR, et al · · 2016 · cited 2× · PMID 26492107 · DOI 10.3851/imp3001
Zika Virus Immunoglobulin G Seroprevalence among Young Adults Living with HIV or without HIV in Thailand from 1997 to 2017.
Choyrum S, Wangsaeng N, Nechba A, Salvadori N, et al · · 2022 · cited 1× · PMID 35215960 · DOI 10.3390/v14020368

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other Institut de Recherche pour le Developpement trials

Trials by the same sponsor.

NCT07181278 — Optimization of Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of De · NA · recruiting
NCT05581212 — TB Case-Finding, Treatment and Prevention Intervention in Thailand · NA · not yet recruiting
NCT06503393 — SENOVIE France - Therapeutic Mobility and Breast Cancer · completed
NCT05466630 — Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis · NA · completed
NCT05091489 — ANRS 12415 - Quali PrEP Cambodia · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01511237 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut de Recherche pour le Developpement
Last refreshed: 20 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01511237.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing